Summary

Nintedanib plus docetaxel significantly improved progression-free survival independent of histology, and prolonged overall survival for non-small cell lung cancer (NSCLC) with adenocarcinoma histology. Adverse events were generally manageable with dose reductions and symptomatic treatment. This article reports on results from the BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in Second-Line Non-Small Cell Lung Cancer study [LUME-Lung 1; NCT00805194; Reck M et al. J Clin Oncol 2013 (suppl; abstr LBA8011)], a placebo-controlled Phase 3 trial of nintedanib plus docetaxel in patients with locally advanced/metastatic NSCLC progressing after first-line therapy.